ClinicalTrials.gg
RecruitingNCT07227818Updated Sep 25, 2026

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

A Phase 3 interventional study of NBI-1117568 and Placebo in Schizophrenia, sponsored by Neurocrine Biosciences. Recruiting at 25 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Sep 25, 2026First sites in Puerto Rico and SerbiaSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.

Planned enrollment
2nd of 16
560 · median 165
Started
2025
with 4 others
Phase 3
6 of 16
4 open now
Registered
15th of 16
by date

Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2025, is one of 6 in phase 3, and was the 15th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • NBI-1117568
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the , Fifth Edition, Text Revision (DSM-5-TR) criteria.
  • Participant had the initial diagnosis of schizophrenia ≥1 year before screening.
  • Participant has had a positive response to ≥1 antipsychotic therapy (other than clozapine) at a therapeutic dose.

Key Exclusion Criteria:

  • Participant has an unstable or poorly controlled medical condition or chronic disease (including history of neurological [including dementing illness, myasthenia gravis], hepatic, renal, cardiovascular, gastrointestinal, pulmonary, , or endocrine disease that may affect study participation or results) or within 30 days before Day 1.
  • Participant has any laboratory abnormalities suggestive of , poorly managed, or unmanaged undiagnosed disease.
  • Participant has a history of clozapine treatment for treatment-resistant psychosis.
  • Participant has a history of a stay in a psychiatric inpatient facility for ≥30 consecutive days (other than for purely social reasons or due to participation in a different clinical trial) during the 90 days before screening.
  • Participant has initiated or increased intensity of nonpharmacological psychosocial therapeutic treatment within 3 weeks before screening or is expected to change throughout the length of the study.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
560 participants (estimated)

Study arms

  • Experimental
    NBI-1117568

    All participants will receive NBI-1117568 during the Open-label Stabilization Period, then will be randomized to receive NBI-1117568 during the Double-blind Treatment Period.

    Drug: NBI-1117568

  • Placebo comparator
    Placebo

    All participants will receive NBI-1117568 during the Open-label Stabilization Period, then will be randomized to receive placebo matching NBI-1117568 during the Double-blind Treatment Period.

    Drug: NBI-1117568 · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time From Randomization to Relapse

    Time frame: Up to approximately 30 weeks

07

Study locations

23 of 25 sites recruiting
  • Neurocrine Clinical Site
    Garden Grove, California 92845, United States
    Recruiting
  • Neurocrine Clinical Site
    La Habra, California 90631, United States
    Recruiting
  • Neurocrine Clinical Site
    Lemon Grove, California 91945, United States
    Recruiting
  • Neurocrine Clinical Site
    Oceanside, California 92056, United States
    Recruiting
  • Neurocrine Clinical Site
    Torrance, California 90504, United States
    Recruiting
  • Neurocrine Clinical Site
    West Hills, California 91307, United States
    Completed

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Hollywood, Florida 33024, United States
    Recruiting
  • Neurocrine Clinical Site
    Maitland, Florida 32751, United States
    Recruiting
  • Neurocrine Clinical Site
    Miami, Florida 33122, United States
    Recruiting
  • Neurocrine Clinical Site
    Miami, Florida 33155, United States
    Recruiting
  • Neurocrine Clinical Site
    Tampa, Florida 33629, United States
    Recruiting
  • Neurocrine Clinical Site
    West Palm Beach, Florida 33024, United States
    Recruiting
  • Neurocrine Clinical Site
    Atlanta, Georgia 30318, United States
    Recruiting
  • Neurocrine Clinical Site
    Boston, Massachusetts 02116, United States
    Recruiting
  • Neurocrine Clinical Site
    Flowood, Mississippi 39232, United States
    Recruiting
  • Neurocrine Clinical Site
    Marlton, New Jersey 08054, United States
    Recruiting
  • Neurocrine Clinical Site
    Cedarhurst, New York 11516, United States
    Recruiting
  • Neurocrine Clinical Site
    New York, New York 10029, United States
    Recruiting
  • Neurocrine Clinical Site
    New York, New York 10032, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    The Bronx, New York 10461, United States
    Recruiting
  • Neurocrine Clinical Site
    DeSoto, Texas 75115, United States
    Recruiting
  • Neurocrine Clinical Site
    Bellevue, Washington 98007, United States
    Recruiting
  • Neurocrine Clinical Site
    San Juan, 00918, Puerto Rico
    Recruiting
  • Neurocrine Clinical Site
    Gornja Toponica, 18202, Serbia
    Recruiting
  • Neurocrine Clinical Site
    Kragujevac, 34000, Serbia
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2029, 43 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 43 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2025
First posted
Nov 13, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2029
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added — first sites in Puerto Rico and Serbia. 2 sites changed recruiting status (1 now completed, 1 now withdrawn)
Show 2 sites
  • Neurocrine Clinical Site · West Hills, United StatesRecruiting→Completed
  • Neurocrine Clinical Site · New York, United StatesRecruiting→Withdrawn
Show 5 added (2 United States, 2 Serbia, 1 Puerto Rico)
  • Neurocrine Clinical Site · Marlton, United States
  • Neurocrine Clinical Site · DeSoto, United States
  • Neurocrine Clinical Site · San Juan, Puerto Rico
  • Neurocrine Clinical Site · Gornja Toponica, Serbia
  • Neurocrine Clinical Site · Kragujevac, Serbia
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    5 sites added — first sites in Puerto Rico and Serbia. 2 sites changed recruiting status (1 now completed, 1 now withdrawn)
    Show 2 sites
    • Neurocrine Clinical Site · West Hills, United StatesRecruiting→Completed
    • Neurocrine Clinical Site · New York, United StatesRecruiting→Withdrawn
    Show 5 added (2 United States, 2 Serbia, 1 Puerto Rico)
    • Neurocrine Clinical Site · Marlton, United States
    • Neurocrine Clinical Site · DeSoto, United States
    • Neurocrine Clinical Site · San Juan, Puerto Rico
    • Neurocrine Clinical Site · Gornja Toponica, Serbia
    • Neurocrine Clinical Site · Kragujevac, Serbia
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07227818
Responsible party
Sponsor
First posted
Nov 13, 2025
Start date
Dec 16, 2025
Primary completion
Jul 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Sep 25, 2026

Study contacts

Neurocrine Medical Information Call Center
Contact
medinfo@neurocrine.com
1-877-641-3461
Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Direclidine

Start the discussion